ADME-Toxicology Testing: Market Research Report

Date: January 2, 2015
Pages: 269
Price:
US$ 4,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ADDBF2DD00CEN
Leaflet:

Download PDF Leaflet

ADME-Toxicology Testing: Market Research Report
This report analyzes the worldwide markets for ADME-Toxicology Testing in US$ Million by the following Segments: Toxicology Testing (In-Vivo, & In-Vitro), and ADME Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 73 companies including many key and niche players such as -
  • ACEA Biosciences, Inc.
  • ADMEcell, Inc.
  • Agilent Technologies, Inc.
  • Albany Molecular Research, Inc.
  • Bayer Technology Services GmbH
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
ADME-Tox – An Introduction
Toxicology Testing
ADME Testing

II. EXECUTIVE SUMMARY

1. OUTLOOK

ADME–Tox Testing Gains Traction
A Peek into the Impact of ADME-Tox Screening on New Drug Discovery

Table 1. Phase-I Clinical Trial Failures Before and After the Advent of Preclinical ADME/Pharmacokinetics (includes corresponding Graph/Chart)
Table 2. Factors Leading to Failure of Drugs in Phase II Clinical Trials: Percentage Breakdown of Number of Cases for Efficacy, Pharmacokinetics, Toxicity and Others (includes corresponding Graph/Chart)
Table 3. Factors Leading to Failure of Drugs in Phase III Clinical Trials: Percentage Breakdown of Number of Cases for Efficacy, Pharmacokinetics, Toxicity and Others (includes corresponding Graph/Chart)
Table 4. Drug Withdrawals Due to Toxicity Issues (1990-2010): Percentage Share Breakdown of Number of Drugs Withdrawn Due to Cardiotoxicity, Hepatotoxicity and Others (includes corresponding Graph/Chart)

Current and Future Analysis
US and Europe Dominate, Asia-Pacific Lends Growth Momentum
Growth Momentum Shifts Away from In Vivo Technologies; In Vitro Technologies to Lead the Charge

2. INDUSTRY OVERVIEW

Pharma Industry Renews Focus on Cost Optimization

Table 5. US R&D Productivity Trends in Pharma Industry (2006- 2013) (includes corresponding Graph/Chart)

China and India: Hot Spots for R&D Investment

Table 6. Percentage Breakup of Global R&D Spending by Region (2012) (includes corresponding Graph/Chart)

ADME-Tox Assays - An Overview
Introduction of Early In Vitro ADMET Studies
Growing Prominence of Cell-based Assays in DrugDiscovery and ADME Analysis

Table 7. Global Market for Cell-based Assays by Application (2013): Percentage Breakdown of Value Sales for ADME Analysis, Basic Research, Drug Discovery, Predictive Toxicology and Others (includes corresponding Graph/Chart)
Table 8. Global Market for Cell-based Assays (2013): Percentage Breakdown of Value Sales by Segment (includes corresponding Graph/Chart)
Table 9. Global Market for Cell-based Assays (2013): Percentage Breakdown of Value Sales by End-User (includes corresponding Graph/Chart)

Major Types of Cell-Based HTS Assays for Drug Screening
CROs Expand Presence
Drug Discovery Outsourcing and Type of Services Outsourced
M&A - Order of the Day

3. MARKET DYNAMICS

Focus Shifts to Innovative Approaches
Need for Better Models: A Major Factor Driving Innovation in the Market
In Silico and In Vitro- the Way to Go
In Vitro Testing Systems and Its Relevance in Drug Development
Growing Inclination towards In-vitro Assays for Toxicology Studies
In Silico ADME-Tox Growing at a Fast Clip
Advantages of Using In Silico Approaches
Factors Hindering Growth

3-D TISSUE BIOASSAYS TO ENHANCE IN VITRO TOXICITY TESTING

3D PRINTED ORGAN TISSUES FOR TOXICOLOGY TESTING: ON THE HORIZON

Increasing Use of Cell-Based Assays over Other Methods in Toxicity Testing
Rising Number of Drug Targets Surge Demand for Cell-Based Assays
Growing Focus on the Development of Reproducible and Robust Cell-based Assays
Functional Assays: An Effective Way of Predicting Specific Toxic Effects
GPCR Targets to Drive Growth in Functional Cell Assay Market
New Alternatives for Early-Stage Toxicology Testing
Stem Cells Exude Great Potential in Drug Toxicity Testing
Primary Hepatocytes Become Standard Tool for Evaluation in Hepatic Metabolism
Cryopreserved Human Hepatocytes- The Current Buzzword in the Industry
Cardiotoxicity Testing Gains Prominence
Cell Imaging-Gaining Popularity
Computational Models on Rise
Adoption of Data Management Systems
Drug Transporter Analysis Becoming Part of ADME Assessment
Regulatory Bodies Focus on Transporter Mediated DDIs

4. DRUG DISCOVERY & DEVELOPMENT

Overview

Table 10. Escalating Costs of New Drug Development Over the Decades (includes corresponding Graph/Chart)

Drug Discovery and Development
Target identification
Target Validation
Lead Identification
Lead Optimization
Pharmaceuticals - R&D Value Chain
Pre-Clinical Testing
Clinical Trials
Clinical Trials - The Time Line
Drug Discovery Technologies
Innovation in Screening Guarantees Success for Drug Discovery Programs

5. PRODUCT OVERVIEW

ADME-Tox – An Introduction
Absorption
Distribution
Metabolism
Excretion
Toxicity
ADME-Tox Profiling
ADME-Tox Screening Technologies
ADME-Tox Parameters
Cell Based Assays
Liver Cell Based Assays
Intestinal Cell Based Assays
Kidney Cell Based Assays

6. PRODUCT INNOVATIONS/INTRODUCTIONS

BioReliance Unveils Select In Vitro ADME and Toxicology Testing Services
Cyprotex Releases SenCeeTox Technology with Enhanced Capabilities
Cyprotex Expands In-House Drug Transporter Services
Cyprotex Launches KeratinoSens Service
Simulations Plus Introduces ADMET Predictor Version 7.
Lena Biosciences Launches SeedEZ 3D Cell Culture Products
Sigma Life Science to Introduce Genetically- Modified HepaRG Human Liver Cell Line
Hepregen Introduces First Rat Hepatopac DMPK Assay Kits
Hepregen Introduces Human HepatoPac Kit for Metabolite Identification and Profiling
Hepregen Unveils First Human Hepatopac Assay Kit for Toxicology Applications
Hurel Introduces Cell-Based In Vitro Testing Product Suite
Plexpress Rolls Out TRACPACK DOG INDUCTION ADMET Service for Canine
Simulations Plus Rolls Out New Version of ADMET Predictor Software Program
Cyprotex Introduces eCiphrCardio for Cardiotoxicity Services
Cyprotex Introduces New CellCiphr Premier
Simulations Plus Introduces New Version of ADMET Predictor
Cyprotex and InSphero Unveil New Liver Toxicology Screening Service
Cyprotex Unveils PXR/AhR Nuclear Receptor Activation Assay and Lysosomotropism Service
Celerion Expands ADME Suite
Plexpress Extends Pre-Validated Probe Line under TRAC System

7. RECENT INDUSTRY ACTIVITY

Takara Bio Acquires Cellectis AB
WuXi PharmaTech Acquires XenoBiotic Laboratories
Merck KGaA to Take Over Sigma-Aldrich
Dassault Systèmes Acquires Accelrys
Organovo Collaborates with J&J for 3D Bioprinting Drug Discovery Research
Taconic and IVAL Enter into Agreement
Charles River to Acquire Galapagos’ Argenta and BioFocus Service Divisions
Simulations Plus Signs 5-Year RCA with the US FDA
Simulation Plus Inks Distributor Agreement with RILD
Harlan CRS Enters into Strategic Alliance with Bertin Pharma
Pharmaron Receives GLP Certification from the CFDA for GLP Toxicology Facilities
Cyprotex Acquires CeeTox
Taconic Announces Name Change
Rosa & Co. Acquires Entelos Holdings’ Consulting Service Business
Thermo Fisher Scientific Acquires Life Technologies
AMRI and Ono Pharmaceutical Enter into 5-Year Service Agreement
Xceleron Partners with JCL Bioassay
Taconic Enters into Distribution Agreement with Vivo Bio Tech
Charles River Takes Over Vital River
Taconic and Medicyte Sign Marketing and Sales Agreement
Taconic and InVivos Enter into Distribution Agreement
Simulations Plus Enter into Material Transfer Agreement with NIEHS
Simulations Plus Collaborates with Bayer HealthCare
QPS Holdings and Hepregen Announce Partnership
Qualyst Transporter Solutions and Hepregen Enter into Co-Development and Co-Marketing Agreement
Elsevier Takes Over Aureus Sciences
EDSL Purchases Stake in Cerep
Argenta and Antabio Ink Collaboration Agreement
Cyprotex Selects IRIS Accounting Software
Galapagos Creates a New Service Division
Bioreclamation Acquires CelsisIVT
Sigma-Aldrich Acquires Worldwide License for iPS Cell Patent Portfolio of Kyoto University
Cyprotex and Sigma Life Science Ink Licensing Agreement
Ono Pharmaceutical Enters into an Agreement with BioFocus
Cyprotex Enters into a Collaboration Agreement with Pfizer
Plexpress to Enter into Partnership with SBW
Cyprotex Forms Strategic Alliance with Sirius Analytical Instruments
WCP Acquires Sterling Reference Laboratories

8. FOCUS ON SELECT PLAYERS

ACEA Biosciences, Inc. (US)
ADMEcell, Inc. (US)
Agilent Technologies, Inc. (US)
Albany Molecular Research, Inc. (US)
Bayer Technology Services GmbH (Germany)
Beckman Coulter, Inc. (US)
BioreclamationIVT, LLC (US)
Cambridge Cell Networks Ltd. (UK)
Cerep SA (France)
CompuDrug International, Inc. (US)
Cyprotex PLC. (UK)
CeeTox, Inc. (US)
Dassault Systèmes (France)
Entelos, Inc. (US)
Elsevier B. V. (The Netherlands)
Eurofins ADME BIOANALYSES SAS (France)
Galapagos NV (Belgium)
Molecular Discovery Ltd. (UK)
MultiCASE, Inc. (US)
Optivia Biotechnology (US)
PerkinElmer, Inc. (US)
Pharmaron, Inc. (US)
Promega Corporation (US)
Qualyst, Inc. (US)
Simulations Plus, Inc. (US)
Taconic Farms, Inc. (US)
Takara Bio Europe AB (Sweden)
Tecan Group Ltd. (Switzerland)
Thermo Fisher Scientific, Inc. (US)
Xceleron, Inc. (US)

9. GLOBAL MARKET PERSPECTIVE

Table 11. World Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 12. World Historic Review for ADME-Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 13. World 12-Year Perspective for ADME- Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)
Table 14. World Recent Past, Current & Future Analysis for Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 15. World Historic Review for Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 16. World 12-Year Perspective for Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)
Table 17. World Recent Past, Current & Future Analysis for Toxicology Testing by Segment - In-Vivo and In-Vitro Toxicology Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 18. World Historic Review for Toxicology Testing by Segment - In-Vivo and In-Vitro Toxicology Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 19. World 12-Year Perspective for Toxicology Testing by Segment - Percentage Breakdown of Revenues for In-Vivo and In-Vitro Toxicology Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)
Table 20. World Recent Past, Current & Future Analysis for In-Vivo Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 21. World Historic Review for In-Vivo Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 22. World 12-Year Perspective for In-Vivo Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)
Table 23. World Recent Past, Current & Future Analysis for In-Vitro Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 24. World Historic Review for In-Vitro Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 25. World 12-Year Perspective for In-Vitro Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)
Table 26. World Recent Past, Current & Future Analysis for ADME Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 27. World Historic Review for ADME Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 28. World 12-Year Perspective for ADME Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
Current & Future Analysis
Clinical Trials Market in the US
Product/Service Launches
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 29. US Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 30. US Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 31. US 12-Year Perspective for ADME- Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

2. CANADA

Market Analysis

Table 32. Canadian Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 33. Canadian Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 34. Canadian 12-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis
Current & Future Analysis
Strategic Corporate Development
B. Market Analytics

Table 35. Japanese Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 36. Japanese Historic Review for ADME- Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 37. Japanese 12-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Current & Future Analysis
Clinical Trials Market in Europe
B. Market Analytics

Table 38. European Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 39. European Historic Review for ADME- Toxicology Testing by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 40. European 12-Year Perspective for ADME-Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)
Table 41. European Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 42. European Historic Review for ADME- Toxicology Testing by Segment – Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 43. European 12-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

4A. FRANCE

A. Market Analysis
Current & Future Scenario
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 44. French Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 45. French Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 46. French 12-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Current & Future Analysis
Strategic Corporate Development
Bayer Technology Services GmbH - A Key German Player
B. Market Analytics

Table 47. German Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 48. German Historic Review for ADME- Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 49. German 12-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

4C. ITALY

Market Analysis

Table 50. Italian Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 51. Italian Historic Review for ADME- Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 52. Italian 12-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

A. Market Analysis
Current & Future Analysis
Product/Service Launches
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 53. UK Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 54. UK Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 55. UK 12-Year Perspective for ADME- Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

4E. REST OF EUROPE

A. Market Analysis
Current & Future Analysis
Clinical Trials Market in Select Regions
Russia

Table 56. Russian Clinical Trials Market by Trial Type (2014): Percentage Breakdown of Number of Trials for Bioequivalence Studies (Foreign Sponsors), Bioequivalence Studies (Local Sponsors), Global Multi-Center Clinical Trials, Local Clinical Trials (Foreign Sponsors), and Local Clinical Trials (Local Sponsors) (includes corresponding Graph/Chart)
Table 57. Russian Clinical Trials Market by Hosting Country (2014): Percentage Breakdown of Trials for Germany, Russia, Switzerland, United Kingdom, United States and Others (includes corresponding Graph/Chart)

Spain
Garnering Investments from Multinational Pharma Companies

Table 58. Apportion of R & D Expenditure by Study Phase in Spain: 2014 (includes corresponding Graph/Chart)

Product/Service Launches
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 59. Rest of Europe Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 60. Rest of Europe Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 61. Rest of Europe 12-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Current & Future Analysis
Asia: The Most Preferred Destination for Clinical Trials
An Overview of Clinical Trials Market in Select Countries in the Region
China
Pharmaceutical Outsourcing Sector in China- An Overview
Implementation of GLP Standard Makes Data Internationally Acceptable
Use of Non-Human Primates- A Key Feature of Chinese Pharmaceutical Sector
Going Ahead. . . .
India
A Thriving Clinical Trials Market

Table 62. Cost of Conducting Clinical Trials: India Vs. US (In US$ Thousand) (includes corresponding Graph/Chart)

Australia
Australia Makes Strong Pitch for Clinical Trials
Major Challenges Facing Australian Clinical Trials Market
Strategic Corporate Developments
B. Market Analytics

Table 63. Asia-Pacific Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 64. Asia-Pacific Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 65. Asia-Pacific 12-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

6. REST OF WORLD

A. Market Analysis
Current & Future Analysis
Latin America: An Emerging Market for Clinical Trials
The Middle East - Brimming with Potential for Clinical Trials

Table 66. The Middle East Clinical Trial Market (2014): Percentage Breakdown of Registered Clinical Trials in Israel, Turkey, Iran, Saudi Arabia, Lebanon, and Rest of Middle East (includes corresponding Graph/Chart)

B. Market Analytics

Table 67. Rest of World Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 68. Rest of World Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 69. Rest of World 12-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 73 (including Divisions/Subsidiaries - 81)
The United States (48)
Canada (2)
Japan (2)
Europe (24)
  France (4)
  Germany (3)
  The United Kingdom (7)
  Spain (1)
  Rest of Europe (9)
Asia-Pacific (Excluding Japan) (5)
Skip to top


Ask Your Question

ADME-Toxicology Testing: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: